Skip to main content
Clinical Trials/IRCT20211206053304N1
IRCT20211206053304N1
Completed
Phase 1

Initial evaluation of the therapeutic efficacy of 177Lu-FAPI in patients with various end-stage metastatic cancers resistant to standard therapies

Iran University of Medical Sciences0 sites10 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • the patient should be able to understand and sign off the informed consent.
  • The patient should be able to understand and follow the treatment protocol.
  • Patients should be older than 18\.
  • The patients life expectancy should be over 6 months.
  • patients should show no response to the standard treatment.
  • The 68Ga\-FAPI PET scan or 99mTc\-FAPI SPECT scan should show 3 times more uptake of radiopharmaceutical in tumor to liver of the patients.
  • the patient with progressive disease should be included.

Exclusion Criteria

  • The patients who have received therapeutic radiopharmaceuticals like, 223Ra, 188Re, 186Re, 153Sm during last 6 months.
  • The patients are under systemic therapies like chemotherapy, immunotherapy, or biological treatment for cancer.
  • The patients who have been under any research treatment during 28 days before entrance in this study.
  • The patients who have shown any known allergy to the therapeutic radiopharmaceuticals.
  • The patients who have congestive heart failure.

Outcomes

Primary Outcomes

Not specified

Similar Trials